An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2
L. Zhang, K. K. Narayanan, L. Cooper, K. K. Chan, C. A. Devlin, A. Aguhob, K. Shirley, L. Rong, J. Rehman, A. B. Malik, E. Procko
bioRxiv · Mar 28, 2022 · PreprintMicrobiology